MarketLens

Log in
Stock AnalysisPro

What Do the SYNAPSE-CMT Phase 2a Results Mean for NMD Pharma

1 months ago
SHARE THIS ON:

What Do the SYNAPSE-CMT Phase 2a Results Mean for NMD Pharma

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What Do the JADE101 Phase 1 Interim Results Reveal

What Do the JADE101 Phase 1 Interim Results Reveal

1 months ago
What Happened with aTyr Pharma's Initial Phase 3 Trial

What Happened with aTyr Pharma's Initial Phase 3 Trial

2 months ago
What Do the Povorcitinib Trial Results Mean for Incyte

What Do the Povorcitinib Trial Results Mean for Incyte

3 months ago
What Do UNFI's Mixed Q2 Results Really Mean for Investors

What Do UNFI's Mixed Q2 Results Really Mean for Investors

4 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCryptoNew Release

You may also like

Stock News•1 day ago

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Scholar Rock updated the timing for a CHMP opinion on its apitegromab MAA for spinal muscular atrophy. The regulatory decision timeline remains uncertain pending the committee's review.
MAA
Stock News•3 weeks ago

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment

Sionna Therapeutics' NBD1 stabilization approach could enhance CFTR function beyond current CF standards. SION-719 and SION-451 face pivotal readouts in summer 2026. A $289.9M cash runway through 2028...
SION
Stock News•1 months ago

SYNAPSE-CMT Phase 2a Clinical Study Data Presented in Late-Breaking Oral Presentation at 2026 PNS Annual Meeting

NMD Pharma presented Phase 2a SYNAPSE-CMT data on ignaseclant for Charcot-Marie-Tooth disease at the 2026 PNS Annual Meeting. The late-breaking oral presentation covered safety and efficacy results fr...
CMT
Stock News•1 months ago

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinued a Phase 3 riliprubart study for CIDP due to low efficacy, potentially reinforcing Argenx's Vyvgart position in the market.

Breaking News

View All →
Earnings
Financials
Regional Banks
Corporate Earnings
Earnings Surprise
Biotech & Pharma
Commercial Real Estate (CRE)
Enterprise Software Spending
Healthcare
REITs

Featured Articles

Congressional Caution on Cadence: Why Rep. Donalds' Sales Signal Near-Term Headwinds for CDNS

Congressional Caution on Cadence: Why Rep. Donalds' Sales Signal Near-Term Headwinds for CDNS

2 hours ago
Bank of America: Congressional Exits Signal a Peak Amidst AI's Banking Reshaping

Bank of America: Congressional Exits Signal a Peak Amidst AI's Banking Reshaping

2 hours ago
STMicroelectronics' AI Pivot: A 384x P/E Hides a Powerful 2026 Earnings Rebound

STMicroelectronics' AI Pivot: A 384x P/E Hides a Powerful 2026 Earnings Rebound

8 hours ago

Top Headlines

View More →
Stock News•1 hour ago

Nvidia (NVDA) Outperforms Broader Market: What You Need to Know

Stock News•2 hours ago

Intel: Insane Valuation Going Into Earnings

Stock News•2 hours ago

Morgan Stanley Analysts Say Sentiment Has Gotten ‘Too Negative' on Software Stocks. These Are Their Picks

Stock News•2 hours ago

Oracle's Preferred Is The Better Trade Below $180

Stock News•3 hours ago

Why Sandisk Shares Are Tumbling and What Investors Should Know